Ibogaine in Texas

What SB 2308 does

Senate Bill 2308 was signed by Governor Greg Abbott at the Texas Capitol on 11 June 2025. Authored by Senator Tan Parker, it authorises clinical drug trials of ibogaine to research its potential in opioid use disorder, depression and post-traumatic stress disorder.

The mechanism is a matching arrangement rather than a straight grant. The Texas Health and Human Services Commission provides state matching funds for an FDA drug trial run by a consortium that must include a drug developer, an institution of higher education and a hospital. The commission may disburse nothing until it has verified that the consortium matched the state’s contribution from sources other than the state. That is wider than private capital: federal grants, philanthropy and university funds all qualify.

SB 2308 itself carries no money. Two instruments are doing two jobs, and almost every account of Texas merges them.

The conditions people attribute to the funding are in one instrument and the funding is in the other.

The state also took a stake. Section 491.060 allocates not less than 20 percent of all revenue from intellectual property and commercial rights arising from the trials to Texas, and a quarter of the state’s share may be appropriated only to programmes assisting veterans.

What SB 2308 does not do

Ibogaine’s schedule is federal, and no state can change it. Texas also lists it in Penalty Group 2 of its own Health and Safety Code, alongside mescaline, so possession without a prescription is a felony under section 481.116, a state jail felony at the smallest quantities and more serious above one gram, as well as a federal offence. Everything a Schedule I listing implies still applies: no physician may prescribe it, and no clinic may lawfully administer it outside an approved protocol.

The programme is not an exemption from the federal system. It is an investment in moving a drug through that system, which is a slower and much narrower thing.

What happened next, and why it matters

The programme’s first phase did not go as designed.

In December 2025 the Health and Human Services Commission selected a public-university consortium led by UTHealth Houston with UTMB Health, operating as IMPACT, for Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma, and drawing in ten further Texas institutions.

The universities announced they had been “awarded $50 million”. The commission holding the money describes the position differently, and has done so on its own website since at least May 2026:

The piece that would not come together was the drug developer. SB 2308 requires a consortium to include one, and Texas invited proposals. On 31 March 2026 Lieutenant Governor Dan Patrick and Speaker Dustin Burrows announced that multiple proposals from drug companies had failed to meet the standard set for state funds, and that Texas would proceed with its own medical researchers instead. The partner Texas went looking for in industry is now the state’s own medical schools.

That is worth sitting with, because it is the most informative fact about the programme. A state offered $50 million to any company that could bring an ibogaine product through an FDA trial, on condition that the company matched the sum and committed 20 percent of future revenue to Texas, and the offer did not attract a proposal it judged adequate. Whatever one concludes from that, it is a poor fit with the account in which ibogaine is a proven treatment held back only by politics.

What it means if you live in Texas

Nothing has changed about access, and nothing will for some years.

There is no lawful route to ibogaine in Texas outside enrolment in an approved trial, and the trials are still being organised. The route Texans actually take is the border: Mexico has never scheduled ibogaine, which is why the clinics are there and why the drive is short. Being lawfully treated there says nothing about carrying anything back, which is a separate federal offence. Even a completed Phase 1 study establishes tolerability in a small group, not efficacy. A treatment that a physician can offer you requires Phase 3 results, FDA approval and then rescheduling, in that order.

Texas in context

Texas was first and remains by far the largest, but it is no longer alone. Arizona, Indiana, California, Mississippi, Kentucky, Oklahoma, Colorado and Louisiana have all enacted ibogaine legislation since, and Kentucky’s research framework survived a governor’s veto in April 2026, though the appropriation it started with was stripped before passage. Only Arizona and Indiana actually attached money.

None of them legalises the substance either. Colorado is the only one that did something categorically different, having decriminalised personal possession by ballot measure in 2022. The pattern across the other eight is the same: money for research, inside the federal pathway, on the theory that approval is the only route that ends anywhere. The federal position explains why that is the only route available to a state, and the status by country table shows what the alternative regimes look like elsewhere.